Abbott withdraws Meridia from market
On Oct. 8, Abbott Laboratories voluntarily withdrew its weight loss drug Meridia (sibutramine) from the market in response to a request from the U.S.…
News
New safety information for Invirase
The U.S. Food and Drug Administration announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir).…
How to revive the FDA
The Oct. 6 New England Journal of Medicine includes a perspective on how to “revive” the U.S. Food and Drug Administration. Read it here.
Amgen, FDA announce voluntary recall of Epogen and Procrit
On Sept. 24, Amgen and the U.S. Food and Drug Administration announced that Amgen is voluntarily recalling certain lots of Epogen and Procrit (Epoetin…
Hospira infusers recalled
On Sept. 10, the U.S. Food and Drug Administration announced the recall of the Hospira Symbiq One-Channel and Two-Channel Infusers because of the potential…
Free online course on FDA drug regulation
Access “The Past, Present, and Future of FDA Human Drug Regulation,” a free educational program from the U.S. Food and Drug Administration is available…
Engage Introducer recalled
On Aug. 13, the U.S. Food and Drug Administration (FDA) announced the recall of 6 French Engage Introducers manufactured between April 27 and June…
FDA posting postmarketing drug safety evaluations
You can access U.S. Food and Drug Administration (FDA) postings on postmarketing drug safety evaluations online. For more information, click here.
The Avandia saga
Read an interesting editorial about Avandia here. A U.S. Food and Drug Administration panel recommended keeping the drug on the market, but increasing warnings…
Avastin may lose metastatic breast cancer indication
An U.S. Food and Drug Administration (FDA)-advisory panel has voted to strip Avastin’s indication for metastatic breast cancer because the drug is not effective…
FDA halts Avandia trial enrollment
The U.S. Food and Drug Administration (FDA) notified GlaxoSmithKline that the post-marketing trial of Avandia (rosiglitazone) is on “partial clinical hold,” meaning no new…
Infusion pump resource from FDA
The U.S. Food and Drug Administration has devoted a section of its website to infusion pump safety. It includes a link for reporting an…
Abbott withdraws Meridia from market
On Oct. 8, Abbott Laboratories voluntarily withdrew its weight loss drug Meridia (sibutramine) from the market in response to a request from…
New safety information for Invirase
The U.S. Food and Drug Administration announced that new safety information has been added to the label for the HIV antiviral drug…
How to revive the FDA
The Oct. 6 New England Journal of Medicine includes a perspective on how to “revive” the U.S. Food and Drug Administration. Read…
Amgen, FDA announce voluntary recall of Epogen and Procrit
On Sept. 24, Amgen and the U.S. Food and Drug Administration announced that Amgen is voluntarily recalling certain lots of Epogen and…
Hospira infusers recalled
On Sept. 10, the U.S. Food and Drug Administration announced the recall of the Hospira Symbiq One-Channel and Two-Channel Infusers because of…
Free online course on FDA drug regulation
Access “The Past, Present, and Future of FDA Human Drug Regulation,” a free educational program from the U.S. Food and Drug Administration…
Engage Introducer recalled
On Aug. 13, the U.S. Food and Drug Administration (FDA) announced the recall of 6 French Engage Introducers manufactured between April 27…
FDA posting postmarketing drug safety evaluations
You can access U.S. Food and Drug Administration (FDA) postings on postmarketing drug safety evaluations online. For more information, click here.
The Avandia saga
Read an interesting editorial about Avandia here. A U.S. Food and Drug Administration panel recommended keeping the drug on the market, but…
Avastin may lose metastatic breast cancer indication
An U.S. Food and Drug Administration (FDA)-advisory panel has voted to strip Avastin’s indication for metastatic breast cancer because the drug is…
FDA halts Avandia trial enrollment
The U.S. Food and Drug Administration (FDA) notified GlaxoSmithKline that the post-marketing trial of Avandia (rosiglitazone) is on “partial clinical hold,” meaning…
Infusion pump resource from FDA
The U.S. Food and Drug Administration has devoted a section of its website to infusion pump safety. It includes a link for…
Poll
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.